Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 13/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 3/20 | 0.38 |
| ▸ | AKT2 | P31751 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3351130 | 0.97 | HDAC1 (0.43) | HDAC1HTTAKT1AKT2NPC1 | |
| SCHEMBL198502 | 0.94 | HDAC1 (0.41) | HDAC1AKT1AKT2NPC1RAB9A | |
| SCHEMBL3357501 | 0.91 | AKT1 (0.48) | HDAC1HTTAKT1AKT2NPC1 | |
| SCHEMBL3353637 | 0.91 | HDAC1 (0.43) | HDAC1AKT1AKT2HDAC3HDAC2 | |
| SCHEMBL3356972 | 0.89 | HDAC1 (0.44) | HDAC1AKT1AKT2HDAC3HDAC2 | |
| SCHEMBL3356593 | 0.89 | NPC1 (0.42) | HDAC1HTTAKT1AKT2NPC1 | |
| SCHEMBL3351761 | 0.89 | HDAC1 (0.44) | HDAC1AKT1AKT2HDAC3HDAC2 | |
| SCHEMBL3356058 | 0.89 | MAPK14 (0.42) | HDAC1SMN1; SMN2 | |
| SCHEMBL3351914 | 0.88 | AKT1 (0.47) | HDAC1HTTAKT1AKT2NPC1 | |
| SCHEMBL3354346 | 0.88 | HDAC1 (0.43) | HDAC1AKT1AKT2HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198299-B2 | Cycloalkylidene and heterocycloalkylidene inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-06-12 | — | — | US | claimed |
| US-20100022543-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-01-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022543-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC2 | HDAC1 1/4885HTT 478/4885AKT1 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.